{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-017017","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2022-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.301746+00:00","generated_at":"2026-06-25T00:46:38.944034+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Lixte Biotechnology appoints Dr. René Bernards as independent director","bullets":["Dr. René Bernards appointed to board; he is a leader in molecular carcinogenesis at Netherlands Cancer Institute.","Co-founded four biotech companies; member of Royal Netherlands Academy of Sciences, AACR Fellow.","Presented new data at AACR on effectiveness of lead compound LB-100 with various anti-cancer agents.","Compensation: one-time $100k cash fee and annual $40k payable quarterly in lieu of stock options."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-017017","json":"https://secwatch.observer/filing/0001493152-22-017017.json","markdown":"https://secwatch.observer/filing/0001493152-22-017017.md","text":"https://secwatch.observer/filing/0001493152-22-017017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315222017017/0001493152-22-017017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315222017017/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T00:46:38.944034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"492333918c","claim":"Dr. René Bernards was appointed as director at LIXTE BIOTECHNOLOGY HOLDINGS, INC..","evidence_excerpt":"Effective as of June 15, 2022, the Company’s Board of Directors (the “Board”) appointed Dr. René Bernards to the Board as an independent director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315222017017/0001493152-22-017017-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}